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Etent Overlap
n Patients Undergoing
rug-Eluting Stent Implantation
read with interest the paper by Räber et al. (1) comparing patients
ith multiple drug-eluting stents (DES) in a vessel with overlap
ith patients with multiple DES in a vessel without overlap and
atients with 1 DES/vessel. The authors demonstrated that major
dverse cardiac events were more common in patients with DES
verlap than in the other groups at 3 years.
First, because the original study demonstrated a significant
ifference between sirolimus- and paclitaxel-eluting stent groups
2), it would be of great help if the authors would provide data
tratified by stent type. Second, overlapping stent implantation was
erformed for dissection in some cases (28 of 138, 20%). Dissec-
ion might be a cause of creatine kinase elevation (myocardial
nfarction) rather than overlapping stent implantation itself. To
larify this point, it would be of great help if the authors would
rovide data about peri-procedural creatine kinase elevation and its
ssociation with dissection. Third, target lesion revascularization
eems to be determined on a per-patient basis. Because there were
wice as many lesions/patient (2.0, 394 in 199 patients) in patients
ith multiple DES in a vessel without overlap compared with the
ther groups (1.0, 138 in 134 patients; 1.1, 778 in 679 patients),
er-patient analysis might overestimate target lesion revasculariza-
ion rate in patients with multiple DES in a vessel without overlap.
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eply
e appreciate the interest of Dr. Kaneda in our study (1) reporting
n the angiographic and long-term clinical outcome in patients
ith first-generation drug-eluting stent (DES) overlap and takehe opportunity to present clinical outcome data up to 3 yearstratified/stent type (Table 1) (2). Crude event rates among
atients with DES overlap (A), patients with multiple DES in a
essel without overlap (B), and patients with a single stent in a
essel (C) were similar between stent types. Corresponding crude
nd adjusted hazard ratios (HRs) varied to some extent between
tent types, but confidence interval (CI) overlapped widely, and
ests for interaction between HRs and stent type were negative,
uggesting the absence of a relevant impact of stent type on the
linical outcome among patients with DES overlap.
Dr. Kaneda appropriately raises the question of whether dissec-
ions were the source of peri-procedural myocardial infarction
MI) rather than overlapping stent implantations per se. Indeed,
eri-procedural MI, defined as any MI occurring within 48 h of
he index procedure were more frequent among patients with DES
verlap due to dissection (11.1%) as compared with patients with
ES overlap related to other indications (0.9%, relative risk: 13.3,
5% CI: 1.3 to 133.0, p  0.03). When excluding peri-procedural
Is from the analyses, however, we found HRs of MI comparing
atients with DES overlap and patients with multiple DES in a
essel without overlap similar to those reported in our paper (1):
rude HR: 1.30 (95% CI: 0.47 to 3.58); adjusted HR: 2.07 (95%
I: 0.56 to 7.75). Accordingly, dissections might have contributed
n part to the observed impact of stent overlap but do not explain
he adverse effect emerging during longer-term follow-up in terms
f ischemic end points (death or MI) and restenosis.
We concur with Dr. Kaneda that patients with multiple target
esions are more likely to experience target lesion revascularizations
TLRs) than patients with single lesions. In our study, the hazard
f TLR was 1.88 times higher in patients with 2 lesions (95% CI:
.20 to 2.96) and 3.05 times higher in patients with 3 lesions (95%
I: 1.50 to 6.22) as compared with patients with single lesions
p for trend 0.01). We therefore adjusted, as reported in Table 5
f our article (1), analyses for the number of lesions in the
ultivariable model. The HR of TLR comparing patients with
ES overlap and patients with multiple DES without overlap was
.26 in the crude analysis (95% CI: 0.76 to 2.11), 1.83 in an
nalysis adjusted for the number of target lesions (95% CI: 1.06 to
.19), and 1.94 in the fully adjusted analysis reported in Table 5 of
ur article (95% CI: 1.05 to 3.58) (1).
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Table 1 Clinical Events at 3 Years Stratified According to the Type of Stent Implanted
Multiple Stents Crude Analysis Adjusted Analysis*
Overlap
(A)†
No Overlap
(B)‡
Single Stent
(C)§
A vs. B HR
(95% CI)
A vs. C HR
(95% CI) p Value
A vs. B HR
(95% CI)
A vs. C HR
(95% CI) p Value
Sirolimus, n  503
Total no. of patients 54 102 347
Death 5 (9.3) 7 (6.9) 22 (6.3) 1.34 (0.43-4.23) 1.47 (0.5–3.87) 0.74 2.86 (0.84–9.68) 1.70 (0.57–5.06) 0.34
Cardiac death 3 (5.6) 5 (4.9) 12 (3.5) 1.13 (0.27–4.73) 1.62 (0.46–5.73) 0.67 2.78 (0.59–13.11) 1.79 (0.42–7.63) 0.43
MI 5 (9.3) 6 (5.9) 14 (4) 1.61 (0.49–5.26) 2.38 (0.86–6.60) 0.24 2.40 (0.59–9.69) 1.52 (0.41–5.60) 0.53
Death or MI 10 (18.5) 13 (12.7) 34 (9.8) 1.47 (0.65–3.36) 1.96 (0.97–3.97) 0.16 2.55 (0.99–6.57) 1.95 (0.85–4.46) 0.11
TLR 8 (14.8) 18 (17.6) 27 (7.8) 0.80 (0.35–1.83) 1.93 (0.88–4.25) 0.01 0.95 (0.33–2.79) 0.86 (0.29–2.51) 0.78
TVR 9 (16.7) 21 (20.6) 34 (9.8) 0.77 (0.35–1.68) 1.75 (0.84–3.64) 0.01 1.07 (0.40–2.86) 0.92 (0.35–2.44) 0.87
Definite stent thrombosis 1 (1.9) 6 (5.9) 10 (2.9) 0.31 (0.04–2.54) 0.64 (0.08–5.00) 0.28 NA NA NA
MACEs 13 (24.1) 22 (21.6) 42 (12.1) 1.10 (0.56–2.19) 2.09 (1.12–3.89) 0.01 1.84 (0.80–4.23) 1.57 (0.71–3.45) 0.26
Target vessel failure 13 (24.1) 25 (24.5) 48 (13.8) 0.95 (0.49–1.87) 1.81 (0.98–3.35) 0.02 1.49 (0.66–3.36) 1.43 (0.66–3.08) 0.36
Paclitaxel, n  509
Total no. of patients 80 97 332
Death 8 (10.0) 10 (10.3) 14 (4.2) 0.96 (0.38–2.43) 2.42 (1.02–5.77) 0.04 1.10 (0.38–3.22) 3.82 (1.16–12.57) 0.03
Cardiac death 3 (3.8) 5 (5.2) 12 (3.6) 0.72 (0.17–3.0) 1.05 (0.30–3.74) 0.77 0.72 (0.13–3.91) 1.01 (0.18–5.66) 0.99
MI 6 (7.5) 6 (6.2) 18 (5.4) 1.19 (0.38–3.70) 1.41 (0.56–3.56) 0.75 1.60 (0.40–6.38) 1.94 (0.62–6.11) 0.26
Death or MI 13 (16.3) 15 (15.5) 28 (8.4) 1.03 (0.49–2.16) 1.96 (1.02–3.79) 0.05 1.18 (0.50–2.80) 2.62 (1.10–6.24) 0.03
TLR 19 (23.8) 14 (14.4) 39 (11.7) 1.73 (0.87–3.45) 2.17 (1.25–3.75) 0.02 3.25 (1.45–7.26) 1.47 (0.74–2.91) 0.27
TVR 21 (26.3) 18 (18.6) 47 (14.2) 1.48 (0.79–2.78) 2.01 (1.20–3.36) 0.03 2.84 (1.35–5.96) 1.18 (0.61–2.25) 0.63
Definite stent thrombosis 5 (6.3) 2 (2.1) 12 (3.6) 3.05 (0.59–15.7) 1.79 (0.63–5.08) 0.35 NA NA NA
MACEs 21 (26.3) 20 (20.6) 53 (16.0) 1.3 (0.70–2.39) 1.74 (1.05–2.88) 0.09 2.20 (1.08–4.50) 1.31 (0.69–2.46) 0.14
Target vessel failure 23 (28.8) 23 (23.7) 61 (18.4) 1.24 (0.69–2.20) 1.66 (1.03–2.69) 0.09 2.07 (1.06–4.07) 1.09 (0.59–2.00) 0.78
Values are n (%). *Adjusted for diabetes, lesion length, reference vessel diameter, number of lesions, lesion classification, and the presence of acute coronary syndrome. †Patients with multiple drug-eluting stents in a vessel with overlap. ‡Patients with multiple stents in
a vessel without overlap. §Patients with a single stent in the vessel. p values for differences in hazards across the 3 groups (A, B, C) in crude and adjusted analyses.
CI  confidence interval; HR  hazard ratio; MACE major adverse cardiovascular event; MI myocardial infarction; NA  a multivariable model could not be fitted due to the low number of events and estimated are not available; TLR  target lesion revascularization;
TVR  target vessel revascularization.
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-Acetylcysteine Somewhere
etween Scylla and Charybdis
hiele et al. (1) report a study dealing with the impact of
-acetylcysteine (NAC) administered simultaneously on prevent-
ng iodinated contrast agent-induced nephropathy and reperfusion
njury in patients with ST-segment elevation myocardial infarction
reated by percutaneous coronary intervention (PCI). The study
ncluded 126 patients compared with a placebo-treated group.
heir results as well as conclusions generate many noteworthy
ssociations.
Free oxygen radicals are regarded as variable typically involved
ither in reperfusion of previously ischemic tissue anywhere in the
ody or in specific interaction between the iodinated contrast agent
nd the filtration capacity of the kidney, with the latter being most
ronounced with previous kidney injury.
As a result, the exact mode of action of NAC (defense against
ree oxygen radicals) in the LIPSIA-N-ACC (Prospective, single-
lind, placebo-controlled, randomized Leipzig Immediate Percu-
aneouS coronary Intervention Acute myocardial infarction
-ACC) trial still remains unclear. First, most importantly, it
hould be taken into account that all patients had normal serum
reatinine level, perhaps a crucial fact for further evaluation. A
ifferent study design including patients with a priori elevated
erum creatinine levels (roughly at least 140 mol/l) would be
ore appropriately representative by making the same size of the
atient group sufficient for final statistical analysis. Even so, the
ncidence of contrast agent-induced nephropathy incidence in
he NAC-treated arm of the LIPSIA-N-ACC trial was reported
o be lower by 6% when compared with the placebo group. Second,
nother fact raising some doubt is the selected dose of NAC: 1,200
g of NAC before PCI cannot be regarded as a high dose even if
dministered intravenously. In experimental studies, an approxi-
ate dose of 100 mg NAC/kg body weight has been used before
nduction of injury (i.e., this is de facto the total dose of NAC used
n the present trial including doses administered within 48 h
ost-procedurally). Third, likewise, the distribution of NAC
etween the 2 target organs remains unclear: the kidney exposed to
he burden of the iodinated contrast agent versus the ischemic/
eperfused myocardium (i.e., the proportion of NAC entering the
aforementioned organs and even more so, after recirculation
hrough the pulmonary vessel bed: a Killip class 2 was reported
n 11% of the NAC group and in 14% of the placebo group). The
AC bolus and, actually, the whole dose administered is figura-
ively somewhere between Scylla and Charybdis, with the former
eing nephron stress and the latter ischemic and reperfusion
yocardial injury. Fourth, the enigma for researchers to be yet
esolved continues to be which “high” dose of NAC is actually
high” in terms of being functionally adequate for both the organ iompartments in question. The authors (1) report a 20%
eduction of oxidative stress markers in the NAC group: this is,
owever, a biochemical parameter, perhaps not yet reaching a
evel high enough to have a functional or possibly structural
mpact on the injured myocardial area. Fortunately enough,
lmost all patients were receiving angiotensin-converting en-
yme inhibitors/angiotensin II type 1 antagonists and statins—
opefully comparable?—in both study groups. Fifth, earlier
uman studies (for details, see appropriate references in Thiele
t al. [1]) used different types of myocardial reperfusion/
oronary artery recanalization: fibrinolysis (2) involving opening
f the artery by gradual dissolution of a fresh red thrombus,
hereas current PCI is “an instantaneous switch for coronary
lood flow from the closed to open position.” Sixth, the
forementioned makes it unclear whether mode NAC action on
he myocardial microvasculature is the same in both reperfusion
echniques. Finally, judging by experimental animal studies,
AC seems to exert more beneficial effects on the filtration
apacity of the kidney in its more developed injury (3).
The reader could now perhaps say the study simply failed.
owever, from a scientific point of view, I personally feel this
ell-designed study has provided many provoking stimuli for
urther research and definitely is not to be perceived as a breaking
oint for making indiscriminate decisions in our current clinical
ractice.
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eply
e thank Prof. Sochman for his interest in our paper (1) and agree
hat the exact mode of action of N-acetylcysteine (NAC) for the
efense against free oxygen radicals—as shown in our LIPSIA-N-
CC (Prospective, single-blind, placebo-controlled, randomized
eipzig Immediate PercutaneouS coronary Intervention Acute
yocardial infarction N-ACC) trial—remains unclear. However,n contrast to the first of 7 statements by Prof. Sochman, not all
